### 1 **High-Resolution Cryo-EM Structure Determination of** a**-Synuclein – A Prototypical Amyloid Fibril**

- 2 3 Authors: Juan C. Sanchez<sup>1,2,3</sup>, Josh Pierson<sup>1</sup>, Collin G. Borcik<sup>1,4</sup>, Chad M. Rienstra<sup>1,2,3,4,7</sup>, Elizabeth R.  $Wright<sup>1,2,3,5,6,7,*</sup>$
- 5
- 6  $^{\frac{1}{2}}$ Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA 53706
- 
- <sup>2</sup> Biophysics Graduate Program, University of Wisconsin-Madison, Madison, WI, USA 53706<br><sup>3</sup> Biotechnology Training Program, University of Wisconsin-Madison, Madison, WI, USA 53706
- 9 <sup>4</sup> National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, WI, USA 53706
- <sup>5</sup> 10 Cryo-Electron Microscopy Research Center, UW-Madison, Madison, WI, USA, 53706
- 11<br>12 <sup>6</sup>Midwest Center for Cryo-Electron Tomography, Department of Biochemistry, University of Wisconsin, Madison, WI, USA, 53706
- 13 <sup>7</sup>Morgridge Institute for Research, UW-Madison, Madison, WI, USA, 53715
- 14<br>15 \*Elizabeth R. Wright
- 
- 16<br>17 17 **Email:** erwright2@wisc.edu

# 18 **Abstract**

19<br>20

The physiological role of  $\alpha$ -synuclein ( $\alpha$ -syn), an intrinsically disordered presynaptic neuronal protein, is believed 21 to impact the release of neurotransmitters through interactions with the SNARE complex. However, under certain 22 cellular conditions that are not well understood,  $\alpha$ -syn will self-assemble into  $\beta$ -sheet rich fibrils that accumulate and form insoluble neuronal inclusions. Studies of patient derived brain tissues have concluded 23 and form insoluble neuronal inclusions. Studies of patient derived brain tissues have concluded that these inclusions are associated with Parkinson's disease, the second most common neurodegenerative disorder, and other 24 are associated with Parkinson's disease, the second most common neurodegenerative disorder, and other synuclein<br>25 related diseases called synucleinopathies. In addition, repetitions of and specific mutations to the SNC 25 related diseases called synucleinopathies. In addition, repetitions of and specific mutations to the SNCA gene, the 26 gene that encodes α-syn, results in an increased disposition for synucleinopathies. The latest advances in cryo-EM structure determination and real-space helical reconstruction methods have resulted in over 60 *in vit* 27 structure determination and real-space helical reconstruction methods have resulted in over 60 *in vitro* structures of 28  $\alpha$ -syn fibrils solved to date, with a handful of these reaching a resolution below 2.5 Å. Here, we provide a protocol<br>29 for  $\alpha$ -syn protein expression, purification, and fibrilization. We detail how sample quality 29 for  $\alpha$ -syn protein expression, purification, and fibrilization. We detail how sample quality is assessed by negative stain transmission electron microscopy (NS-TEM) analysis and followed by sample vitrification using 30 stain transmission electron microscopy (NS-TEM) analysis and followed by sample vitrification using the Vitrobot 31 Mark IV vitrification robot. We provide a detailed step by step protocol for high resolution cryo-EM st 31 Mark IV vitrification robot. We provide a detailed step by step protocol for high resolution cryo-EM structure<br>32 determination of  $\alpha$ -syn fibrils using RELION and a series of specialized helical reconstruction tools  $32$  determination of  $\alpha$ -syn fibrils using RELION and a series of specialized helical reconstruction tools that can be run<br>33 within RELION. Finally, we detail how ChimeraX, Coot, and Phenix are used to build and refine within RELION. Finally, we detail how ChimeraX, Coot, and Phenix are used to build and refine a molecular model 34 into the high resolution cryo-EM map. This workflow resulted in a 2.04 Å structure of  $\alpha$ -syn fibrils with excellent resolution of residues 36 to 97 and an additional island of density for residues 15 to 22 that had n 35 resolution of residues 36 to 97 and an additional island of density for residues 15 to 22 that had not been previously<br>36 reported. This workflow should serve as a starting point for individuals new to the neurodegenera 36 reported. This workflow should serve as a starting point for individuals new to the neurodegeneration and structural 37 biology fields. Together, this procedure lays the foundation for advanced structural studies of  $\alpha$ -synuclein and other amyloid fibrils. amyloid fibrils. 39<br>40 **Key Features:** 41 • *In vitro* fibril amplification method yielding twisting fibrils that span several micrometers in length and are suitable for cryo-EM structure determination.

- 
- 43 High-throughput cryo-EM data collection of neurodegenerative fibrils, such as alpha-synuclein.<br>44 Use of RELION implementations of helical reconstruction algorithms to generate high-resolutio 44 • Use of RELION implementations of helical reconstruction algorithms to generate high-resolution 3D structures of a-synuclein fibrils. 45 of a-synuclein fibrils.<br>46 • Brief demonstration c
- Brief demonstration of the use of ChimeraX, Coot, and Phenix for molecular model building and refinement.

47<br>48 48 **Keywords:** cryo-EM | helical reconstruction | alpha-synuclein | amyloid proteins | neurodegeneration | vitrification



49 50

**51 Graphical overview of α-synuclein fibrilization and cryo-EM structure determination.** α-synuclein protein expression and purification is followed by a fibrilization protocol yielding twisting filaments that span se 52 expression and purification is followed by a fibrilization protocol yielding twisting filaments that span several<br>53 micrometers in length and are validated by negative stain transmission electron microscopy (NS-TEM). T 53 micrometers in length and are validated by negative stain transmission electron microscopy (NS-TEM). The sample is then vitrified, followed by cryo-EM data collection. Real-space helical reconstruction is performed 54 sample is then vitrified, followed by cryo-EM data collection. Real-space helical reconstruction is performed in<br>55 RELION to generate an electron potential map that is used for model building. RELION to generate an electron potential map that is used for model building.

## 56 **Introduction and Background.**

57<br>58

58 Amyloid formation within neurons has been well documented to cause neurodegeneration in patients leading to a<br>59 variety of diseases including Alzheimer's (AH), Parkinson's disease (PD), Lewy Body disease (LB), and mult 59 variety of diseases including Alzheimer's (AH), Parkinson's disease (PD), Lewy Body disease (LB), and multiple 60 system atrophy (MSA) [1-3]. The formation of amyloids is due to protein aggregation resulting in helical, 61 filamentous assemblies with cross  $\beta$ -sheet quaternary structure (Figure 1) [4]. Amyloid filaments interact

61 filamentous assemblies with cross  $\beta$ -sheet quaternary structure (Figure 1) [4]. Amyloid filaments interact with 62 different cellular components such as membranes, cytoskeletal factors, and other filaments to form in different cellular components such as membranes, cytoskeletal factors, and other filaments to form inclusion bodies

63 that disrupt cellular processes and ultimately lead to cell death [2]. These inclusion bodies are prominent in<br>64 postmortem brains of patients who have suffered from these neurodegenerative diseases, and early investig postmortem brains of patients who have suffered from these neurodegenerative diseases, and early investigation of

65 inclusion bodies revealed the presence of filamentous a-synuclein  $(\alpha$ -syn) [1,2].  $\alpha$ -syn is a small (14.4 kDa)

66 intrinsically disordered protein whose physiological role remains elusive.  $\alpha$ -syn has the capability to bind to the 67 SNARE complex and associate with vesicles at the neuronal axon terminus providing evidence that i

67 SNARE complex and associate with vesicles at the neuronal axon terminus providing evidence that it may have an impact on neurotransmitter release, vesicle docking and vesicle trafficking [5-8]. However, upon misfolding

impact on neurotransmitter release, vesicle docking and vesicle trafficking [5-8]. However, upon misfolding,  $\alpha$ -syn

69 first forms oligomeric aggregates that eventually undergo fibrilization, these fibrils display the highly ordered cross

 $70$  B-sheets classically found in amyloids [9,10]. These, in turn, form the extended filaments that cause neuropathological changes in the brain and are specifically responsible for PD, LB, and MSA. Disea 71 neuropathological changes in the brain and are specifically responsible for PD, LB, and MSA. Diseases caused by

72  $\alpha$ -synuclein in this manner are called synucleinopathies [11].

73 74 The high-resolution structure presented here of filamentous wild-type α-syn is of a helical filament composed of 2 protofilaments and each turn (or rung) of the filament is comprised of 2 copies (one per protofilament 75 protofilaments and each turn (or rung) of the filament is comprised of 2 copies (one per protofilament) of α-syn facing nearly 180 degrees from each other (Figure 1). Between the monomers that make up each protofilament there 77 is a hydrophobic interface composed of residues 50-57, similar to previously solved structures of filamentous  $\alpha$ -syn<br>78 [12-14]. This interface is stabilized by salt-bridges and pseudo screw symmetry, as previously r 78 [12-14]. This interface is stabilized by salt-bridges and pseudo screw symmetry, as previously reported [12,13]. For  $\alpha$ -svn, there are 7 different missense familial mutations commonly found in patients who have a hig 79  $\alpha$ -syn, there are 7 different missense familial mutations commonly found in patients who have a higher disposition<br>80 for synucleinopathies (A30P, E46K, H50Q, G51D, A53E, A53T, and A53V) [15-21]. Interestingly, 6 of for synucleinopathies (A30P, E46K, H50Q, G51D, A53E, A53T, and A53V) [15-21]. Interestingly, 6 of these 81 familial mutations lie within the core of the structure and may cause destabilization resulting in a variety of different 82 fibril morphologies. The presence of polymorphism has been demonstrated particularly well thro fibril morphologies. The presence of polymorphism has been demonstrated particularly well through the analysis of 83 *in vitro* a-syn fibrils. Fibril twist, crossover distance, packing arrangement, number of protofilaments, interface, 84 tertiary structure, etc. can vary greatly under different micro- and macro-environments. Many different 85 environmental factors such as pH, salt concentrations, temperature, quiescence, and post translational n 85 environmental factors such as pH, salt concentrations, temperature, quiescence, and post translational modifications<br>86 have an impact on fibril morphology—this has led to documentation of more than 60 *in vitro* struct 86 have an impact on fibril morphology—this has led to documentation of more than 60 *in vitro* structural polymorphs 87 of  $\alpha$ -syn in the PDB [22,23]. These structural differences in the *in vitro* filaments can have direct effects on nucleation rates, seeding propensities, and even cytotoxicity [23]. Unfortunately, the ties between th 88 nucleation rates, seeding propensities, and even cytotoxicity [23]. Unfortunately, the ties between these structurally<br>89 distinct *in vitro* polymorphs to those found in sarkosyl-insoluble brain-derived structures rema 89 distinct *in vitro* polymorphs to those found in sarkosyl-insoluble brain-derived structures remains elusive. However,<br>90 evidence suggests that different polymorphs may influence pathologies [24-26]. This is demonstrat 90 evidence suggests that different polymorphs may influence pathologies [24-26]. This is demonstrated by the  $91$  difference in  $\alpha$ -syn folds of the filaments extracted from patients diagnosed with MSA versus PD [27]. difference in  $\alpha$ -syn folds of the filaments extracted from patients diagnosed with MSA versus PD [27].

92<br>93 93 The formation of the filaments responsible for synucleinopathies are propagated in brain tissue by primary  $94$  nucleation events in which  $\alpha$ -syn monomer spontaneously undergoes structural changes resulting in nuclea 94 nucleation events in which  $\alpha$ -syn monomer spontaneously undergoes structural changes resulting in nucleation. This <br>95 nucleation site can then recruit additional  $\alpha$ -syn monomers to bind, thus elongate the fibril [ 95 nucleation site can then recruit additional  $\alpha$ -syn monomers to bind, thus elongate the fibril [28,29]. However, there  $\alpha$  can also be secondary nucleation events in which preformed fibrils are introduced into the ce 96 can also be secondary nucleation events in which preformed fibrils are introduced into the cellular environment as 97 "seeds" [30]. These seeding events are significantly more potent at fibril formation and elongation. 97 "seeds" [30]. These seeding events are significantly more potent at fibril formation and elongation. Remarkably, 98 seeds from a particular polymorph have been shown to recruit wild-type  $\alpha$ -syn, provide a structural seeds from a particular polymorph have been shown to recruit wild-type  $\alpha$ -syn, provide a structural template, and 99 form filaments expressing the polymorph of the seed regardless of whether the endogenous protein recruited is pathogenic or not [31]. A consequence of this prion-like self-replication is that  $\alpha$ -syn fibrils may move 100 pathogenic or not [31]. A consequence of this prion-like self-replication is that  $\alpha$ -syn fibrils may move from cell-to-<br>101 cell spreading cytotoxic polymorphs. cell spreading cytotoxic polymorphs.

102 The introduction of polymorphism has a multifactorial effect on clinical treatments of neurodegenerative diseases.

104 Our understanding of the implications associated with each polymorph on disease progression, pathology, and<br>105 patient outcomes is very limited. In addition, the differences in folding, packing, twists, etc. of each p

105 patient outcomes is very limited. In addition, the differences in folding, packing, twists, etc. of each polymorph introduces complexities in binding sites, affinities, and accessibility for a "one size fits all" drug

introduces complexities in binding sites, affinities, and accessibility for a "one size fits all" drug for

107 synucleinopathies; this is further complicated by evidence that not only are there disease specific morphisms, but evidence shows that each synucleinopathy can exhibit patient-to-patient heterogeneity [32]. Thus, to ov

108 evidence shows that each synucleinopathy can exhibit patient-to-patient heterogeneity [32]. Thus, to overcome these challenges, explore new therapeutic targets, understand specific polymorph effects on neuropathology,

challenges, explore new therapeutic targets, understand specific polymorph effects on neuropathology, and develop

- 110 therapies with patient-specific approaches, solving both patient-derived and *in vitro* amyloid polymorphs should be explored.
- 112

113 Here, we describe a helical reconstruction workflow that we use to solve the structure of *in vitro* assembled<br>114 filamentous  $\alpha$ -syn to a global resolution of 2.04 Å. We purify  $\alpha$ -syn filaments from a reaction in 114 filamentous  $\alpha$ -syn to a global resolution of 2.04 Å. We purify  $\alpha$ -syn filaments from a reaction in which fibril seeding material is combined with monomeric  $\alpha$ -syn. The fibril seeding material provides a template

115 material is combined with monomeric α-syn. The fibril seeding material provides a template for fibril elongation via<br>116 monomer addition over a 6-week incubation period at 37 °C with shaking at 200 rpm. The purified 116 monomer addition over a 6-week incubation period at 37 °C with shaking at 200 rpm. The purified α-syn filaments

- 
- 117 are then imaged using negative stain transmission electron microscopy (NS-TEM) to evaluate sample integrity and<br>118 fibril concentration on the grid. The sample is then applied to grids and plunge frozen, and the vitri
- 118 fibril concentration on the grid. The sample is then applied to grids and plunge frozen, and the vitrified grids are<br>119 used for cryo-EM data collection. We provide a detailed protocol utilizing RELION to reconstruct used for cryo-EM data collection. We provide a detailed protocol utilizing RELION to reconstruct a high-resolution
- 120 cryo-EM electron potential map that is then used for building an atomic model of the fibril (Figure 1B, 1C, 1E). The steps presented here may be applied to studies of various amy loid fibrils and accelerate cryo-EM str
- 121 steps presented here may be applied to studies of various amyloid fibrils and accelerate cryo-EM structure<br>122 determination in the fields neurodegenerative research and medicine.
- determination in the fields neurodegenerative research and medicine. 123
	-



124 **125 Figure 1. Structural features of α-syn fibrils from cryo-EM structures.** A. Cryo-EM structure of full-length α-<br>**126** syn fibril depicting two protofilaments (one in red; one in grey). B. Magnified view of α-syn fib 126 syn fibril depicting two protofilaments (one in red; one in grey). B. Magnified view of  $\alpha$ -syn fibril portraying stacked rungs and filament twist. C. Cross-section of  $\alpha$ -syn fibril electron potential map displayin stacked rungs and filament twist. C. Cross-section of  $\alpha$ -syn fibril electron potential map displaying two  $\alpha$ -syn 128 monomers that make up each protofilament approximately 180 degrees from each other. D. Electron potential map<br>129 of individual  $\beta$ -sheet stacks twisting. E. Model depicting secondary structure of stacking  $\beta$ -sheet 129 of individual β-sheet stacks twisting. E. Model depicting secondary structure of stacking β-sheets. F. Example of rise<br>130 measurement for P2<sub>1</sub> symmetry (Red) and C2 symmetry (Blue). G. Possible packing symmetry bet measurement for P2<sub>1</sub> symmetry (Red) and C2 symmetry (Blue). G. Possible packing symmetry between 131 protofilaments for P21 symmetry (out of register) (Red) and C2 symmetry (in register) (Blue).

132 133

### 134 **Materials and Reagents**

### 135<br>136 136 **Biological materials**

137 1. Plasmid with wild-type  $\alpha$ -syn construct in *E. coli* BL21(DE3)/pET28a-AS [33].

### 138<br>139 139 **Reagents**

- 140 1. LB broth (Invitrogen, catalog number: 12780029)<br>141 2. Bacto Agar (Dot Scientific Inc., catalog number: I
- 141 2. Bacto Agar (Dot Scientific Inc., catalog number: DSA20030-1000)<br>142 3. Magnesium sulfate, MgSO<sub>4</sub> (Fisher Scientific, catalog number: 01-3
- 3. Magnesium sulfate, MgSO<sub>4</sub> (Fisher Scientific, catalog number: 01-337-186)
- 143 4. Calcium chloride, CaCl<sub>2</sub> (Fisher Scientific, catalog number: BP510-500)
- 144 5. Sodium phosphate, NaH<sub>2</sub>PO<sub>4</sub> (Fisher Scientific, catalog number: 01-337-702)<br>145 6. Potassium phosphate, KH<sub>2</sub>PO<sub>4</sub> (Fisher Scientific, catalog number: 01-337-803
- 145 6. Potassium phosphate, KH2PO4 (Fisher Scientific, catalog number: 01-337-803)
- 146 7. Sodium chloride, NaCl (Fisher Scientific, catalog number: S271-500)
- 147 8. IPTG (Fisher Scientific, catalog number: BP1755-10)
- 148 9. Tris-HCl (Fisher Scientific, catalog number: PRH5125)
- 149 10. EDTA (Fisher Scientific, catalog number: AAA1516130)<br>150 11. Kanamycin monosulfate (Thermo Scientific, catalog num
- 150 11. Kanamycin monosulfate (Thermo Scientific, catalog number: 161272.14)<br>151 12. SDS-PAGE gels (Bio-Rad, catalog number: 4561096)
- 151 12. SDS-PAGE gels (Bio-Rad, catalog number: 4561096)<br>152 13. SDS-PAGE Loading Dye (Bio-Rad, catalog number: 1
- 13. SDS-PAGE Loading Dye (Bio-Rad, catalog number: 1610737)
- 153 14. Coomassie Brilliant Blue (TCI, catalog number: 6104-59-2)
- 
- 154 15. BME vitamins (Sigma-Aldrich, catalog number: B6891-100mL)<br>155 16. Sodium azide (Sigma-Aldrich, catalog number: 19-993-1) 16. Sodium azide (Sigma-Aldrich, catalog number: 19-993-1)
- 
- 156 17. Studier trace metal mix (Sigma-Aldrich, catalog number: 41106212)<br>157 18. Ammonium Sulfate (Fisher Scientific, catalog number: A702-500)
- 157 18. Ammonium Sulfate (Fisher Scientific, catalog number: A702-500)<br>158 19. Deuterium oxide,  ${}^{2}H_{2}O$  (Cambridge Isotopes Laboratories, catalog 158 19. Deuterium oxide, <sup>2</sup>H<sub>2</sub>O (Cambridge Isotopes Laboratories, catalog number: DLM-4-1L)
- 159 20. BioExpress Bacterial Cell Media 10X concentrate (U-<sup>13</sup>C, 98%; U-<sup>15</sup>N, 98%; U-D 98%) (Cambridge Isotopes 160 Laboratories, catalog number: CGM-1000-CDN)
- 21. <sup>15</sup>N-NH<sub>4</sub>CI (Cambridge Isotopes Laboratories, catalog number: 39466-62-10)<br>**162** 22. <sup>2</sup>H-<sup>13</sup>C-glucose (Cambridge Isotopes Laboratories, catalog number: CDLM-38
- 162 22. <sup>2</sup>H-<sup>13</sup>C-glucose (Cambridge Isotopes Laboratories, catalog number: CDLM-3813-5)
- 163 23. Sodium deuteroxide, NaO2 H (Cambridge Isotopes Laboratories, catalog number: DLM-45-100)
- 164 24. 2% Uranyl Acetate (UA) (EMS, catalog number: 22400-2)

# 165<br>166

- 166 **Solutions** 1. Kanamycin Stock Solution (1000x, 40 mg/ml) (recipe below)
- 168 2. Kanamycin Stock Solution (1000x, 90 mg/ml) (recipe below)<br>169 3. Conditioning Plate (recipe below)
- 169 3. Conditioning Plate (recipe below)<br>170 4. Pre-Growth Media (recipe below)
- 4. Pre-Growth Media (recipe below)
- 171 5. Wash Buffer (recipe below)
- 172 6. Growth Media (recipe below)
- 173 7. IPTG Stock Solution<br>174 8. Buffer A (recipe belo
- 174 8. Buffer A (recipe below)<br>175 9. Buffer B (recipe below)
- 9. Buffer B (recipe below)
- 176 10. TEN Buffer (recipe below)
- 177 11. Saturated Ammonium Sulfate Solution (recipe below)<br>178 12. Fibrilization Buffer (recipe below)
- 
- 178 12. Fibrilization Buffer (recipe below)<br>179 13. 1% Uranyl Acetate (recipe below) 13. 1% Uranyl Acetate (recipe below)

### 180<br>181 **Recipes**

182 1. Kanamycin Stock Solution (1000x, 40 mg/ml)



- 184 2. Sterilize solution using a 0.22 µm syringe filter (GenClone) and 10 mL syringe (BD)
- 185 3. Aliquot 1000 uL stocks and store at -20<sup>o</sup>C until use.





- 
- 229 2. Heat gently until all ammonium sulfate is dissolved.

230 3. Cool to room temperature. Crystals should form to indicate the solution is saturated.

231<br>232

12. Fibrilization Buffer





233 1. Add NaH<sub>2</sub>PO<sub>4</sub>, EDTA, 0.02% sodium azide solution into <sup>2</sup>H<sub>2</sub>O and H<sub>2</sub>O.

234 2. pH to 7.4 at  $37^{\circ}$ C using 1M NaO<sup>2</sup>H.

235<br>236

13. 1% Uranyl Acetate (UA) 237



238 1. Mix 1-part sterile water with 1-part 2% UA stain (EMS) and filter through a Spin-X centrifuge tube with a 239 0.22 um filter (Costar).  $0.22 \mu m$  filter (Costar).

# 240<br>241 **Laboratory Supplies**

- 242<br>243 1. 10 ml Syringe (BD, catalog number:  $309604$ )
- 
- 244 2.  $0.22$  um filter (GenClone, catalog number: 25-240)<br>245 3.  $100$  mm  $\times$  15 mm Petri dishes (Fisher Scientific, ca 3. 100 mm  $\times$  15 mm Petri dishes (Fisher Scientific, catalog number: S33580A)
- 246 4. 1000 mL filtration system (Fisher Scientific, catalog number: FB12566506)
- 247 5. 50 mL conical tubes (VWR, 525-1074)<br>248 6. 0.45 µm syringe filter (GenClone, catal
- 248 6. 0.45  $\mu$ m syringe filter (GenClone, catalog number: 25-246)<br>249 7. 1.7 mL centrifuge tubes (Denville, catalog number: C2170)
- 249 7. 1.7 mL centrifuge tubes (Denville, catalog number: C2170)<br>250 8. Parafilm (Bemis, catalog number: PM996)
- 250 8. Parafilm (Bemis, catalog number: PM996)<br>251 9. 0.22 μm Spin-X centrifuge tube filter (Cos
- 251 9. 0.22 μm Spin-X centrifuge tube filter (Costar, catalog number: 8160)<br>252 10. 200 mesh carbon film, copper grids (EMS, catalog number: CF200-C
- 252 10. 200 mesh carbon film, copper grids (EMS, catalog number: CF200-CU)<br>253 11. Whatman #1 filter paper (Whatman, catalog number: 1001-090)
- 11. Whatman #1 filter paper (Whatman, catalog number: 1001-090)
- 254 12. Quantifoil R2/1 200 mesh, copper grids (Quantifoil Micro Tools GmbH, catalog number: Q210CR1)<br>255 13. Standard Vitrobot Filter Paper, Ø55/20mm, Grade 595 (Ted Pella, catalog number: 47000-100)
- 255 13. Standard Vitrobot Filter Paper, Ø55/20mm, Grade 595 (Ted Pella, catalog number: 47000-100)

### 256<br>257 **Equipment** 258

- 259 1. HiTrap Q HP anion exchange column (Cytiva, catalog number: 17115401)<br>260 2. Stirred cell concentrator (Amicon, catalog number: UFSC05001)
- 260 2. Stirred cell concentrator (Amicon, catalog number: UFSC05001)<br>261 3. HiPrep 16/60 Sephacryl S100- HR gel filtration column (Cytiva,
- 261 3. HiPrep 16/60 Sephacryl S100- HR gel filtration column (Cytiva, catalog number: 17119501)<br>262 4. 5424 R Microcentrifuge (Eppendorf, catalog number: 05-400-005)
- 262 4. 5424 R Microcentrifuge (Eppendorf, catalog number: 05-400-005)
- 263 5. Grid holder block (Pelco, catalog number: 16820-25)<br>264 6. Plasma Cleaner (Harrick Plasma Inc., catalog number
- 264 6. Plasma Cleaner (Harrick Plasma Inc., catalog number: PDC-32G)<br>265 7. Static dissipator (Mettler Toledo, catalog number: UX-11337-99)
- 7. Static dissipator (Mettler Toledo, catalog number: UX-11337-99)
- 266 8. Style N5 reverse pressure tweezers (Dumont, catalog number: 0202-N5-PS-1)<br>267 9. Talos L120C 120 kV transmission electron microscope (TEM) (Thermo Fishe
- 267 9. Talos L120C 120 kV transmission electron microscope (TEM) (Thermo Fisher Scientific), or equivalent 268 10. Cryo grid box (Sub-Angstrom, catalog number: SB)
- 10. Cryo grid box (Sub-Angstrom, catalog number: SB)
- 269 11. Plasma Cleaner (Harrick Plasma Inc., catalog number: PDC-32G)<br>270 12. Vitrobot Mark IV vitrification robot (Thermo Fisher Scientific)
- 270 12. Vitrobot Mark IV vitrification robot (Thermo Fisher Scientific)<br>271 13. Titan Krios G3i 300 kV transmission electron microscope (TEM
- 271 13. Titan Krios G3i 300 kV transmission electron microscope (TEM) (Thermo Fisher Scientific)
- 272 14. K3-GIF direct electron detector with energy filter (Gatan Inc., AMETEK)<br>273 15. High-performance computing (HPC) cluster with an EPYC Milan 7713P 6
- 273 15. High-performance computing (HPC) cluster with an EPYC Milan 7713P 64-core 2.0GHz CPU (AMD), 512 GB<br>274 RAM, 4x RTX A5000 24GB GDDR6 GPU (NVIDIA), 2x 960GB Enterprise SSD, mirrored OS, 2x 7.68TB 274 RAM, 4x RTX A5000 24GB GDDR6 GPU (NVIDIA), 2x 960GB Enterprise SSD, mirrored OS, 2x 7.68TB
- 275 nVME SSD as 15TB scratch space, dual-port 25GbE Ethernet.

# 276 **Software**

- 277 1. SBGrid (https://sbgrid.org/)<br>278 2. IMOD (https://bio3d.colorae
- 2. IMOD (https://bio3d.colorado.edu/imod/)

- 279 3. RELION (https://relion.readthedocs.io/en/release-4.0/)<br>280 4. MotionCor2 (https://emcore.ucsf.edu/ucsf-software)
- 280 4. MotionCor2 (https://emcore.ucsf.edu/ucsf-software)<br>281 5. Getf (https://sbgrid.org/software/titles/getf)
- 281 5. Gctf (https://sbgrid.org/software/titles/gctf)<br>282 6. Topaz-filament (https://github.com/3dem/to
- 282 6. Topaz-filament (https://github.com/3dem/topaz)<br>283 7. UCSF ChimeraX (https://www.cgl.ucsf.edu/chin
- 283 7. UCSF ChimeraX (https://www.cgl.ucsf.edu/chimerax/)<br>284 8. Coot (https://www2.mrc-lmb.cam.ac.uk/personal/pemsl
- 284 8. Coot (https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/)<br>285 9. PHENIX (https://phenix-online.org/)
- PHENIX (https://phenix-online.org/)

# 286 **Procedure and Results.**

# 287<br>288 288 **A.** a**-synuclein sample preparation**

289 Expression and purification of α-syn protein is performed as reported previously [33]. The protein preparations and fibrilization protocol presented here were developed for joint cryo-EM and NMR studies. Preparations

290 fibrilization protocol presented here were developed for joint cryo-EM and NMR studies. Preparations include the<br>291 use of isotopically labeled reagents that are critical for NMR experiments but are not necessary for use of isotopically labeled reagents that are critical for NMR experiments but are not necessary for cryo-EM. Thus,

292 the  $\alpha$ -syn sample preparation protocol may be adapted for cryo-EM only studies by substituting isotopically labeled reagents with a standard equivalent reagent. reagents with a standard equivalent reagent.

294

295  $\alpha$ -synuclein protein expression

- 296 1. Expression of wild-type  $\alpha$ -syn is performed in *E. coli* BL21(DE3)/pET28a-AS.<br>297 2. Plate transformed cells onto conditioning plate, overnight at 37 °C.
- 297 2. Plate transformed cells onto conditioning plate, overnight at  $37^{\circ}$ C.<br>298 3. Inoculate a 50 mL pre-growth flask with a single colony from the o
- 298 3. Inoculate a 50 mL pre-growth flask with a single colony from the overnight conditioning plate and incubate overnight at 220 rpm at 37 °C until  $OD_{600} = -3$ . 299 overnight at 220 rpm at 37 °C until OD<sub>600</sub> =  $\sim$ 3.<br>300 4. Transfer cells into a 50 mL conical tube (VWR)
- 300 4. Transfer cells into a 50 mL conical tube (VWR) using aseptic techniques. Centrifuge tubes at 5000 rpm for 5<br>301 minutes at 4 °C. Decant supernatant and wash with  $\sim$ 20 mL of cold wash buffer. minutes at 4 °C. Decant supernatant and wash with  $\sim$ 20 mL of cold wash buffer.
- 302 5. Resuspended cells with the growth media in 4x 1L baffled flasks, 250 mL each. At an OD<sub>600</sub> of  $\sim$ 1-1.2, induce 303  $\alpha$ -syn over-expression with the addition of 1 mL of an IPTG stock solution. Incubate at 25 °C with shaking at 304 200 rpm. 200 rpm.
- 305 6. After overnight growth, collect cells and combine for harvesting  $(-15$  hours post-induction). Centrifuge at 5000 rpm for 10 minutes at 4 °C. Decant the supernatant and wash the cell pellet with the wash buffer to r 306 rpm for 10 minutes at 4 °C. Decant the supernatant and wash the cell pellet with the wash buffer to remove residual growth media components. 307 residual growth media components.<br>308 7. Cell pellets may then be frozen and
- 308 7. Cell pellets may then be frozen and stored at -80 ˚C until use. 309

# 310  $\alpha$ -synuclein protein purification

- 311 1. Cells may be lysed via heat denaturation, as  $\alpha$ -syn is thermostable and will be unaffected. Place 50 mL conical 312 tubes (VWR) containing cell paste in boiling water (98˚C) for 30 minutes. Cool cell lysate on ice. Clear the cell 313 lysate by centrifugation at 5000 rpm for 10 minutes at 4 °C.<br>314 2.  $\alpha$ -syn should then be precipitated via addition of a saturated
- 314 2.  $\alpha$ -syn should then be precipitated via addition of a saturated ammonium sulfate solution on ice. Collect  $\alpha$ -syn precipitate via centrifugation at 16900 rpm for 45 minutes at 4 °C and decanting the supernatant. 315 precipitate via centrifugation at 16900 rpm for 45 minutes at 4 °C and decanting the supernatant.<br>316 3. Equilibrate the HiTrap Q HP anion exchange column (Cytiva) with Buffer A.
	- 3. Equilibrate the HiTrap Q HP anion exchange column (Cytiva) with Buffer A.
- 317 4. Resolubilize the  $\alpha$ -syn precipitate with  $\sim$ 5 ml Buffer A. Make sure to filter the resolubilized  $\alpha$ -syn using a 0.45 318  $\mu$ m syringe filter (GenClone). Inject the resolubilized  $\alpha$ -syn to bind to the QFF anion exchange resin (GE 319 Healthcare Life Sciences, Marlborough, MA). Elute using a linear gradient of 0.03–0.6 M NaCl by increa Healthcare Life Sciences, Marlborough, MA). Elute using a linear gradient of 0.03–0.6 M NaCl by increasing 320 the proportion of Buffer B flow through the column. Collect fraction as they come off the column. In our hands,<br>321 fractions containing  $\alpha$ -syn monomer usually elute at about 0.3 M NaCl. fractions containing  $\alpha$ -syn monomer usually elute at about 0.3 M NaCl.
- 322 5. After completion, Run SDS-PAGE to check to determine which fractions (gel bands) contain  $\alpha$ -syn. Take 20 µL 323 samples from each fraction tube from 20% Buffer B to 40% Buffer B. Add 20  $\mu$ L 2x SDS loading dye (Bio-<br>324 Rad) to each sample tube and heat at 90°C for 5 minutes. Run all samples on an SDS-PAGE gel (Bio-Rad). Rad) to each sample tube and heat at 90°C for 5 minutes. Run all samples on an SDS-PAGE gel (Bio-Rad). Use 325 Coomassie Brilliant Blue stain (Sigma-Aldrich) to stain the gel. Examine the stained gel for  $\alpha$ -syn over-326 expression bands. Note that  $\alpha$ -syn tends to run at an apparent size of 18 kDa. Pool these fractions.
- 327 6. Concentrate the  $\alpha$ -syn monomer solution using a stirred cell concentrator (Amicon) using a 3.5 kDa molecular 328 weight cut off filter to a final concentration of  $\sim$ 15 mg/mL. Prewet the concentrator with Buffer A before adding 329  $\alpha$ -syn solution to prevent loss of sample to the filter.<br>330 7. Equilibrate the 16/60 Sephacryl S-200 HR gel filtrati
- 330 7. Equilibrate the 16/60 Sephacryl S-200 HR gel filtration column (GE Healthcare Life Sciences) with TEN 331 Buffer, 5x column volume. Buffer, 5x column volume.
- 332 8. Inject 1 mL of the concentrated  $\alpha$ -syn pool into the loop path of the 16/60 Sephacryl S-100 HR gel filtration column (Cytiva) and run the protocol at 0.5 mL/min until the fraction with an apparent mass of 15 kDa, 333 column (Cytiva) and run the protocol at 0.5 mL/min until the fraction with an apparent mass of 15 kDa, at  $\sim$ 97 334 minutes.
- 335 9. Pool fractions, concentrate to ~15 mg/ml  $\alpha$ -syn using a clean stirred cell concentrator (Amicon) and a 3.5 kDa 336 molecular weight cut off filter. Prewet the unit and filter with TEN buffer before adding  $\alpha$ -syn solution to 337 prevent loss of sample to the filter. prevent loss of sample to the filter.
- 338 10. Purified  $\alpha$ -syn may then be frozen and stored in -80 °C freezer until use. 339

340  $\alpha$ -synuclein fibrilization

- 341 1. Buffer exchange from the TEN buffer to fibrilization buffer. Add purified  $\alpha$ -syn from above to a prewetted 342 (with the fibrilization buffer) stirred cell concentrator (Amicon) and a 3.5 kDa molecular weight cut (with the fibrilization buffer) stirred cell concentrator (Amicon) and a 3.5 kDa molecular weight cut off 343 filter. Dilute 10x with fibrilization buffer and concentrate down to the initial volume. Repeat 3 times to 344 effectively remove TEN buffer and completely exchange to fibrilization buffer. effectively remove TEN buffer and completely exchange to fibrilization buffer.
- 345 2. Purified  $\alpha$ -syn protein in above buffer was concentrated to 15 mg/ml using 3.5 kDa cut off stir cell 346 concentrators and 0.5 ml aliquoted into clean, sterile 1.7 ml Eppendorf tubes (Denville).
- 347 3. Fibril formation may be seeded with ~50 ng of previously made mature  $\alpha$ -syn fibril (in this case: sample used to determine the PDB ID: 2N0A fibril structure). used to determine the PDB ID: 2N0A fibril structure).
	-
- 349 4. Seal the tubes with parafilm (Bermis) for the duration of the incubation.<br>350 5. Incubate at 37 °C and shake at 250 rpm continuously for 3 weeks. The v 350 5. Incubate at 37 °C and shake at 250 rpm continuously for 3 weeks. The viscosity of the fibril solution will greatly increase over time. greatly increase over time.
- 352 6. At the end of 3 weeks, add 100  $\mu$ L of fibrilization buffer and continue the incubation for 3 weeks under the same conditions. 353 same conditions.<br>354 7. After a total of 6
	- After a total of 6 weeks the fibrils at a protein concentration of  $\sim$ 13 mg/ml are ready for TEM analysis.

# 356 **B. Negative stain**

355

357 Fibrilization can be characterized by thioflavin-T (ThT) assays, which leverage the fluorescence signal observed 358 when thioflavin-T binds to fibrils, a property not observed in the presence of purified protein monom 358 when thioflavin-T binds to fibrils, a property not observed in the presence of purified protein monomers [34].<br>359 Although this method is powerful and can even detail fibrilization kinetics, there are limitations in t 359 Although this method is powerful and can even detail fibrilization kinetics, there are limitations in the 360 technique. Specifically, this assay can not specify whether fibrils are twisting, if the fibrils span several 361 micrometers in length, or are small fragments 10s of nanometers in length. For high-resolution cryo-EM<br>362 structure determination, fibrils should be both twisting and span several crossovers. Additionally, fibrils 362 structure determination, fibrils should be both twisting and span several crossovers. Additionally, fibrils should 363 be concentrated to a point where several fibrils span the micrograph but are not crowded or overlap 363 be concentrated to a point where several fibrils span the micrograph but are not crowded or overlapping. This ensures there are enough individual particles for the reconstruction process. To determine if the fibrils po 364 ensures there are enough individual particles for the reconstruction process. To determine if the fibrils possess 365 these qualities, we perform negative stain transmission electron microscopy (NS-TEM) with the following<br>366 procedure to test a range of sample concentrations. We found that a concentration of 6.5 mg/ml (i.e., 1:1 rati 366 procedure to test a range of sample concentrations. We found that a concentration of 6.5 mg/ml (i.e., 1:1 ratio of 367 sample to buffer) was best for our sample on the grid. sample to buffer) was best for our sample on the grid.

- 368 1. Place the desired number of 200 mesh carbon film, copper EM grids (EMS) on a grid holder block (Pelco)<br>369 and using a plasma cleaner PDC-32G (Harrick Plasma Inc.), or equivalent system, to glow discharge grids 369 and using a plasma cleaner PDC-32G (Harrick Plasma Inc.), or equivalent system, to glow discharge grids<br>370 under a 100-micron vacuum for 30 seconds on low (Figure 2, step 1). under a 100-micron vacuum for 30 seconds on low (Figure 2, step 1).
- 371 2. Cut a piece of parafilm (Bemis) to about 2"x4" and demagnetize with a static dissipater (Mettler Toledo) (Figure 2, step 2).  $(Figure 2, step 2).$
- 373 3. Retrieve one glow discharged EM grid using style N5 reverse pressure tweezers (Dumont), or similar tweezers (Figure 2, step 3). 374 tweezers (Figure 2, step 3).<br>375 4. Spot two 50  $\mu$ L drops of ste
- 375 4. Spot two 50  $\mu$ L drops of sterile, Nanopure water and two 50  $\mu$ L drops of 1% UA on to the piece of parafilm (Bemis), ensure the drops do not touch (Figure 2, step 4). (Bemis), ensure the drops do not touch (Figure 2, step 4).
- 377 5. Apply 4  $\mu$ L of the sample to the EM grid and allow the sample to incubate at room temperature for one minute (Figure 2, step 5). 378 minute (Figure 2, step 5).<br>379 6. Blot away the liquid by to
	- 379 6. Blot away the liquid by touching the edge of the EM grid to a piece of filter paper (Whatman) (Figure 2,
- 380 step 6).<br>381 7. Wash the 381 7. Wash the EM grid by touching the face of the EM grid to the 1<sup>st</sup> drop of water, then blot away the liquid as in step 6. Repeat, but this time wash with the  $2<sup>nd</sup>$  drop of water (Figure 2, step 7). in step 6. Repeat, but this time wash with the  $2<sup>nd</sup>$  drop of water (Figure 2, step 7).
- 8. Pre-stain the EM grid by touching the face of the EM grid to the  $1<sup>st</sup>$  drop of  $1\%$  UA, then blot away the stain as in step 6 (Figure 2, step 8). stain as in step 6 (Figure 2, step 8).
- 9. Stain the grid by holding the face of the EM grid to the  $2<sup>nd</sup>$  drop of 1% UA for 15 seconds, then blot away the stain as in step 6 (Figure 2, step 9). 386 the stain as in step 6 (Figure 2, step 9).<br>387 10. Allow the EM grid to dry for at least 5
- 387 10. Allow the EM grid to dry for at least 5 minutes at room temperature before storing the grid in a grid box<br>388 (Figure 2, step 10). Store the grid box in a desiccator or humidity-controlled room until imaging. 388 (Figure 2, step 10). Store the grid box in a desiccator or humidity-controlled room until imaging.
- 389 11. Repeat for additional sample dilutions to assess the sample conditions that may be best suited for cryo-EM 390 analysis. We imaged the sample at a concentration of 13 mg/ml (undiluted), 6.5 mg/ml (2x dilution), and 391 2.6 mg/ml (5x dilution) and found that a concentration of 6.5 mg/ml showed the best sample distribution on 392 the grid (Figure 3).<br>393 Note: Since fibriliza
- 393 Note: Since fibrilization conditions greatly impact the length of the fibrils, and thus sample distribution on 394 the grid, it is important to test each sample by NS-TEM before sample vitrification and crvo-EM data the grid, it is important to test each sample by NS-TEM before sample vitrification and cryo-EM data 395 collection.

- 396 12. Image grids on a Talos L120C 120 kV TEM, or equivalent microscope, at a pixel size of 1.58 Å and a total electron dose of 25  $e/\text{\AA}^2$ . 397 electron dose of 25  $e^{-}/A^2$ .
- 398



399 **400 Figure 2. Negative stain protocol.** Detailed steps for preparing negative stain grids of  $\alpha$ -syn fibrils. The protocol **401** yields lightly stained fibrils allowing for the visualization twisting fibrils comprised o yields lightly stained fibrils allowing for the visualization twisting fibrils comprised of two protofilaments (Figure

402 3). The procedure is repeated spanning a range of fibril concentrations that are imaged by transmission electron microscopy.

## microscopy.

404

405<br>406



**406 Figure 3. Negative stain TEM analysis of α-synuclein fibrils.** Representative micrograph of fibrils lightly **407** stained with 1% UA. The fibrils are comprised of two protofilaments (arrows) and appear to be twisti 407 stained with 1% UA. The fibrils are comprised of two protofilaments (arrows) and appear to be twisting with 408 distinct crossover points (stars). Scale bar, 100 nm. distinct crossover points (stars). Scale bar, 100 nm.

# 409<br>410 410 **C. Sample vitrification**

411 Basic sample vitrification for single particle analysis has become routine in the cryo-EM field. Here, we present 412 a brief workflow of the vitrification process using the Vitrobot Mark IV (Thermo Fisher Scientific) 412 a brief workflow of the vitrification process using the Vitrobot Mark IV (Thermo Fisher Scientific) with blotting 413 conditions that yield grids suitable for cryo-EM data collection. 413 conditions that yield grids suitable for cryo-EM data collection.<br>414 1. Using a plastic syringe (BD), add 60 mL of distilled water t

- 414 1. Using a plastic syringe (BD), add 60 mL of distilled water to the Vitrobot Mark IV water reservoir.<br>415 2. Turn on the Vitrobot Mark IV, set the chamber temperature to 20°C and the relative humidity to 95°
	- 2. Turn on the Vitrobot Mark IV, set the chamber temperature to  $20^{\circ}$ C and the relative humidity to 95%.
- 416 3. Attach standard Vitrobot filter paper (Ted Pella) to the blotting pads and allow the system to equilibrate 417 while to the conditions set in step  $2 (-15 \text{ minutes})$ .
- 418 4. Using a plasma cleaner (Harrick Plasma Inc.), or equivalent system, glow discharge R2/1 200 mesh, copper 419 419 grids (Quantifoil).<br>420 5. Use liquid nitroger
- 420 5. Use liquid nitrogen  $(LN_2)$  to cool the Vitrobot foam dewar, ethane cup, and metal spider.<br>421 6. Once the setup has cooled, condense the ethane in the ethane cup. Be sure to monitor eth
- 421 6. Once the setup has cooled, condense the ethane in the ethane cup. Be sure to monitor ethane and  $LN_2$  levels throughout the vitrification process.
- 422 throughout the vitrification process.<br>423 7. On the Vitrobot, set the wait time to 423 7. On the Vitrobot, set the wait time to 60 seconds and set the drain time to 0.5 seconds. For blot force and 424 blot time it is usually necessary to test a range of parameters that work best. For these fibrils a blot 424 blot time it is usually necessary to test a range of parameters that work best. For these fibrils a blot time 425 between 4 and 5 seconds, and a blot force of -1 to +2 worked well. 425 between 4 and 5 seconds, and a blot force of -1 to +2 worked well.<br>426 8. Using the Vitrobot tweezers, pick up a grid and attached the tweeze
- 426 8. Using the Vitrobot tweezers, pick up a grid and attached the tweezers to the Vitrobot. Select *"continue"* on the screen to raise the tweezers and mount the foam dewar in place. Follow the prompts on the screen to 428 bring the tweezers and dewar into position for sample application.
- 429 9. Apply 4  $\mu$ L of the fibrils to the carbon side of the grid. Select *"continue"* to begin the wait time, then the system will automatically blot and plunge the sample into liquid ethane. 430 system will automatically blot and plunge the sample into liquid ethane.<br>431 10. Once the system has plunged the specimen into the cryogen, transfer the
- 431 10. Once the system has plunged the specimen into the cryogen, transfer the vitrified grid to a labeled grid box and store appropriately. and store appropriately.
- 433 11. Repeat steps 7 to 9 for any additional grids. In addition to duplicate grids, it is always beneficial to test a<br>434 range of blotting conditions and/or sample concentrations. Cryo-EM data was collected on a grid wi 434 range of blotting conditions and/or sample concentrations. Cryo-EM data was collected on a grid with a 435 blot time of 4 seconds and a blot force of +2 at a protein concentration of  $\sim$  6.5 mg/ml. blot time of 4 seconds and a blot force of  $+2$  at a protein concentration of ~6.5 mg/ml.

# 436<br>437

437 **D. Cryo-EM data collection** Data collection parameters should be tailored to the resources available and thus, users should work closely 439 with EM facility staff to optimize the data collection parameters for their individual sample. Here, the data was<br>440 acquired on a Titan Krios G3i FEG-TEM (Thermo Fisher Scientific). The microscope is operated at 300 440 acquired on a Titan Krios G3i FEG-TEM (Thermo Fisher Scientific). The microscope is operated at 300 kV and<br>441 is equipped with a Gatan K3 direct electron detector (Gatan) and a BioQuantum energy filter set at 20eV 441 is equipped with a Gatan K3 direct electron detector (Gatan) and a BioQuantum energy filter set at 20eV<br>442 (Gatan). Correlated-double sampling (CDS) was used to collect dose fractionated micrographs using a de (Gatan). Correlated-double sampling (CDS) was used to collect dose fractionated micrographs using a defocus 443 range of -0.5 to -2.5  $\mu$ m with increments of 0.25  $\mu$ m. Micrographs were collected at a magnification of 444 105,000X with a pixel size of 0.834 Å and a total dose of 40 e<sup>-</sup>/Å<sup>2</sup> (1 e<sup>-</sup>/Å<sup>2</sup>/frame). On average ~2 444 105,000X with a pixel size of 0.834 Å and a total dose of 40 e $\lambda^2$  (1 e $\lambda^2$ /frame). On average ~250 movies 445 were collected per hour using EPU/AFIS (Thermo Fisher Scientific) acquiring 3 shots per hole and multiple 446 holes per stage movement. A representative micrograph at an estimated defocus of  $-2.0 \mu$ m shows twisting 447 fibrils suspended in vitreous ice (Figure 4). fibrils suspended in vitreous ice (Figure 4). 448



449<br>450

Figure 4. Representative cryo-EM micrographs of  $\alpha$ -synuclein fibrils. Motion corrected micrograph of 451 vitrified  $\alpha$ -synuclein fibrils at an estimated defocus of -2.0  $\mu$ m. The fibrils are comprised of two protofilaments 452 (arrows) that are twisting at distinct crossover points (stars). Twisting fibrils are critica 452 (arrows) that are twisting at distinct crossover points (stars). Twisting fibrils are critical for high-resolution structure determination. Scale bar, 100 nm. structure determination. Scale bar, 100 nm.

# 454<br>455

# 455 **E. Cryo-EM data processing of alpha-synuclein fibrils.**

456 Cryo-EM structure determination of amyloid fibrils has revolutionized the fields of neuroscience and <br>457 eurodegenerative medicine, providing key structural details that were previously unattainable by other 457 neurodegenerative medicine, providing key structural details that were previously unattainable by other<br>458 methods. Here, we provide a data processing protocol, that is both detailed and reproducible, to serve as methods. Here, we provide a data processing protocol, that is both detailed and reproducible, to serve as a 459 starting point for those new to cryo-EM and helical reconstruction workflows. The raw micrographs, gain file,<br>460 and the detector mtf file can be accessed at EMPIAR-12229, allowing users to work through the steps belo and the detector mtf file can be accessed at EMPIAR-12229, allowing users to work through the steps below 461 before applying the workflow to new experimental data. We must note that all data sets are unique and possess 462 their own challenges, but this workflow should greatly improve the user's ability to resolve amyloid fibril<br>463 structures. Finally, as with any software, it is best to first become accustomed to the program by complet 463 structures. Finally, as with any software, it is best to first become accustomed to the program by completing the 464 appropriate tutorial datasets. We highly encourage readers to first complete the RELION single parti appropriate tutorial datasets. We highly encourage readers to first complete the RELION single particle tutorial 465 (https://relion.readthedocs.io/en/release-4.0/SPA\_tutorial/index.html) before proceeding with the steps below<br>466 [35].  $[35]$ .

467 Creating a RELION Project<br>468 Create a directory that will h 468 Create a directory that will house the entire RELION project. For simplicity call this directory *a*-<br>469 *syn data processing*. Within this directory you should have two files titled *gain mrc* and *k*3-CDS syn data processing. Within this directory you should have two files titled *gain.mrc* and *k3-CDS-300keV-*





515<br>516

516 **Figure 5. Helical reconstruction workflow for** a**-synuclein fibrils using RELION.** Overview of each 517 RELION job utilized to reconstruct  $\alpha$ -synuclein fibrils to ~2.0 Å. Each job corresponds to the step number 518 in section E.









 *STAR with coordinates,* close the micrograph and repeat the process for the remaining 19 micrographs. If 744 you need to remove points, use the center button and click over an existing point to remove it. Ensure that<br>745 all the micrographs have an even number of picks (i.e. one start point and one end point per segment) and all the micrographs have an even number of picks (i.e. one start point and one end point per segment) and that segments are centered over fibrils. When done picking from all 20 micrographs close the window to finalize the job. 748 <u>I/O:</u><br>749 *Inpu Input micrographs: Select/job023/micrographs\_split1.star Pick start-end coordinates helices? Yes Use autopick FOM threshold? No* Display: *Particle diameter (Å): 100 Scale for micrographs: 0.2 Sigma contrast: 3 White value: 0 Black value: 0 Lowpass filter (Å): 20 Highpass filter (Å): -1 Pixel size (Å): -1 OR: use Topaz denoising? No* 762 Colors:<br>763 *Blue* <> *Blue<>red color particles? No* The output log will list the total number of picks (start and end points). Here, we picked 414 particles (i.e. 207 segments) from 20 micrographs and the coordinates are saved to the *manualpick.star* file located in the 766 directory for this job. The total number of segments may vary due to differences in picking but ensure picks<br>767 are made on all 20 micrographs. 767 are made on all 20 micrographs.<br>768 NOTE: The parameters in the *Di*  NOTE: The parameters in the *Display* tab are for visualization purposes only and do not impact downstream processing steps. 770 NOTE: We observed that in some versions of RELION there is a bug that results in an empty coordinate<br>771 file from the **Manual picking** job. To bypass this error, simply select the **Manual picking** job from the 771 file from the **Manual picking** job. To bypass this error, simply select the **Manual picking** job from the 772 *Finished jobs* section and then click on the *Continue!* button. This will reopen the manual picking GUI *Finished jobs* section and then click on the *Continue!* button. This will reopen the manual picking GUI then, close the window; the coordinate file should now be updated with all the picks saved. There is no need to repick particles or change any settings. 775 10. Particle Extraction (Manual Picks):<br>776 The manually picked segments mus 776 The manually picked segments must now be processed to extract particles for 2D classification. In principle, this step will take user defined parameters to then cut the segments into individual partic 777 principle, this step will take user defined parameters to then cut the segments into individual particles for<br>778 downstream steps (Figure 6B). This is achieved by providing the *number of unique asymmetrical units* an 778 downstream steps (Figure 6B). This is achieved by providing the *number of unique asymmetrical units* and<br>779 *helical rise (Å)* values in the helix tab. RELION will use these values to establish an interbox distance, *helical rise (Å)* values in the helix tab. RELION will use these values to establish an interbox distance, i.e.<br>**780** the spacing between each particle, that will separate overlapping 360-pixel boxes that traverse the len the spacing between each particle, that will separate overlapping 360-pixel boxes that traverse the length of 781 the segment (Figure 6B). Here, we have set the interbox distance to ~38.5 Å (4.82 Å x 8) to increase the 782 number of particles for training purposes. This value will be expanded later once auto-picking is complete.<br>783 Select the **Particle extraction** job, set *Micrograph STAR file* to the *micrograph split1.star* file from 783 Select the **Particle extraction** job, set *Micrograph STAR file* to the *micrograph\_split1.star* file from step 8,<br>784 set *Input coordinates* to the *manualpick.star* file from step 9, then click the *Run!* button. set *Input coordinates* to the *manualpick.star* file from step 9, then click the *Run!* button. 785 I/O: *Micrograph STAR file: Select/job023/micrographs\_split1.star Input coordinates: ManualPick/job024/manualpick.star OR re-extract refined particles? No OR re-center refined coordinates? No Write output in float16? Yes* 791 Extract:<br>792 *Particle Particle box size (pix): 360 Invert contrast? Yes Normalize particles? Yes Diameter background circle (pix): -1 Stddev for white dust removal: -1* Stddev for black dust removal: -1 *Rescale particles? No*











971 15. Auto-Picking (Topaz Picking on the Entire Dataset)<br>972 The trained Topaz model and the optimized picking

956<br>957<br>958









1042 **Figure 7. Determining crossover distance, helical twist, and helical rise.** A. An initial map depicts the 1043 crossover distance observed in twisting fibrils. The crossover distance is described as the length where the<br>1044 fibril turns 180° (red dotted line). Scale bar, 100 nm. B. The crossover distance can be measured (red 1044 fibril turns 180° (red dotted line). Scale bar, 100 nm. B. The crossover distance can be measured (red line)<br>1045 from well aligned 2D classes where the twisting nature of the fibril is observed, this requires a box s from well aligned 2D classes where the twisting nature of the fibril is observed, this requires a box size that 1046 spans a distance that is close to or larger than the crossover distance for an accurate measurement to be<br>1047 hade. Here, a box size of 864 pixels (720 Å) was used for initial crossover estimates. Poor 2D classes a made. Here, a box size of 864 pixels (720 Å) was used for initial crossover estimates. Poor 2D classes are 1048 mis-aligned or blurry preventing crossover distance measurements. C. The helical rise can be determined 1049 from 2D classes with a small box size (360 pixels) extracted at their original pixel size (0.834 Å/pix) that 1050 yield high resolution details (i.e. spacing of the  $\beta$ -sheets). The sigma contrast of the 2D classes 1050 yield high resolution details (i.e. spacing of the  $\beta$ -sheets). The sigma contrast of the 2D classes must be adjusted to visualize the helical layer lines in reciprocal space. From the average power spectrum, a 1051 adjusted to visualize the helical layer lines in reciprocal space. From the average power spectrum, a<br>1052 measurement (red line) can be made from the meridian to the highest intensity layer line, this measurement 1052 measurement (red line) can be made from the meridian to the highest intensity layer line, this measurement 1053 can be used to estimate the helical rise. D. The measurements made in B and C are used to calculate the can be used to estimate the helical rise. D. The measurements made in B and C are used to calculate the 1054 helical rise and the crossover distance. Then, the crossover distance and helical rise are used to calculate the<br>1055 helical twist of the structure. The estimated helical parameters are used for subsequent 3D refinem helical twist of the structure. The estimated helical parameters are used for subsequent 3D refinement steps.

17. 2D Classification (Large Box Size)

1058 Classify the particles to remove junk particles and to estimate the crossover distance. Select the 2D classification job. set *Input images STAR file* to the *particles star* file from step 16, set the additional **classification** job, set *Input images STAR file* to the *particles.star* file from step 16, set the additional parameters below, then click on the "Run!" button. parameters below, then click on the "Run!" button.  $\frac{I/O:}{Innu}$  *Input images STAR file: Extract/job042/particles.star* 1063 CTF: *Do CTF-correction? Yes Ignore CTFs until first peak? Yes* Optimisation: *Number of classes: 50* **Regularisation parameter T: 2**  *Use EM algorithm? Yes Number of EM iterations: 20 Use VDAM algorithm? No* Mask diameter (Å): 710











**Figure 8. Initial model generation.** A. Classes selected from all 2D classes. All classes shown in A are the 1211 classes selected (job 21) from the classes rendered from the trained neural network auto-picking job o 1211 classes selected (job 21) from the classes rendered from the trained neural network auto-picking job on all<br>1212 micrographs (step 17). The green boxes indicate the two classes selected for initial model generation (s 1212 micrographs (step 17). The green boxes indicate the two classes selected for initial model generation (step 1213 18). B-G. Initial maps for the crossover distances 550-800 Å. One showing the cross-section of the refin 1213 18). B-G. Initial maps for the crossover distances 550-800 Å. One showing the cross-section of the refined<br>1214 filament (cross-section location shown by the black crossbar) and the other depicting the entirety of the filament (cross-section location shown by the black crossbar) and the other depicting the entirety of the filament. The commands used to generate (step 19) and rescale (step 20) the initial models are shown.

22. Particle Extraction (Small Box Size):











1373 **Figure 9. 3D Refinement of different crossover distances and 3D classification.** A. Cross-sections, 1374 resolution, and calculated twist and rise of each initial models after 3D refinement (550-800 Å) (step 2 1374 resolution, and calculated twist and rise of each initial models after 3D refinement (550-800 Å) (step 23).<br>1375 Red and Blue squares indicate respective electron potential maps for B. B. Cross-section of the electron 1375 Red and Blue squares indicate respective electron potential maps for B. B. Cross-section of the electron potential maps refined with 600 Å (Red) and 750 Å (Blue) crossovers. Scale bar, 25 Å. C. 3D 1376 potential maps refined with 600 Å (Red) and 750 Å (Blue) crossovers. Scale bar, 25 Å. C. 3D<br>1377 Classifications from 750 Å crossover initial model (step 24). Green box indicates selected 3D 1377 Classifications from 750 Å crossover initial model (step 24). Green box indicates selected 3D class used for<br>1378 further refinement (step 25). further refinement (step 25).





1424<br>1425

1425 **Figure 10. Results of 3D refinements and post-processing steps.** The 3D refinements and their 1426 corresponding post-processed maps of our processing pipeline are depicted here. The step number,<br>1427 secolution, twist, rise, and mask percentages are displayed for each electron potential map. A descri 1427 resolution, twist, rise, and mask percentages are displayed for each electron potential map. A description as<br>1428 to whether the electron potential map display is a result of a 3D refinement job or post-processing jo to whether the electron potential map display is a result of a 3D refinement job or post-processing job is





1461<br>1462 **Figure 11. Mask central Z length coverage.** A. A mask (gray) covering 80% of the map (purple) along the 1463 fibril axis (step 27), used during CTF refinement steps. B. A mask (gray) covering 25% of the map (purple) 1464 along the fibril axis (step 44), used in the final post-processing job (step 45). C. Filament after applying 1465 real-space symmetrization (step 47) to the edge of the box using the *relion helix toolbox* program. Scale 1466 bars, 25 Å. 1467<br>1468

1468 28. Post-Processing<br>1469 The post-process

The post-processing job will recalculate the global resolution with masking, and it will automatically 1470 estimate and apply a B-factor to sharpen the map, further improving the quality of the map. Select the **Post-**1471 **processing** job, set *One of the 2 unfiltered half-maps* to the *run\_half1\_class001\_unfil.mrc* file from step 26, 1472 set *Solvent mask* to the *mask.mrc* file from step 27, set *MTF of the detector (STAR file)* to the *k3-CDS-*1473 *300keV-mtf.star* file that is supplied with EMPIAR-12229. Set the remaining parameters below then click the *Run!* button. 1475 <u>I/O:</u><br>1476 *One* 

- 1476 *One of the 2 unfiltered half-maps: Refine3D/job081/run\_half1\_class001\_unfil.mrc* 1477 *Solvent mask: MaskCreate/job086/mask.mrc*
- 1478 *Calibrated pixel size (Å) -1*
- 
- 1479 **Sharpen:**<br>1480 *Estimate*
- 1480 *Estimate B-factor automatically? Yes* 1481 *Lowest resolution for auto-B fit (Å): 10*
- Use your own B-factor? No
- 1483 *Skip FSC-weighting? No*
- 1484 *MTF of the detector (STAR file): k3-CDS-300keV-mtf.star*
- 1485 *Original detector pixel size: -1*
- 1486 The job estimated a b-factor of -97, and the processed map is saved as *postprocess.mr*c. The job also 1487 calculated a resolution of 2.97 Å with masking and the volume is saved as *postprocess\_mask.mrc* (Figure
- **1488** 10, step 28).<br>**1489** 29. Bayesian Pol 29. Bayesian Polishing (Round 1)





















1923 **Figure 12. Comparison of Fourier Shell Correlation (FSC) plots of** a**-synuclein maps deposited to the EMDB resolving to below 2.3 Å.** The unmasked FSC plots (calculated FSC from deposited half maps, orange) for the deposited maps display a FSC spike at a spatial frequency of 0.4 Å<sup>-1</sup> (~2.4 Å). The mask 1925 orange) for the deposited maps display a FSC spike at a spatial frequency of 0.4  $\text{Å}^{-1}$  (~2.4 Å). The masked FSC plots (author provided FSC, blue) dampen this feature. FSC plots (author provided FSC, blue) dampen this feature.







A

 **Figure 13. Local resolution map of** a**-syn fibril from cryo-EM data.** A. Local resolution map of 1951 filamentous  $\alpha$ -syn depicting loss of resolution towards the end of the fibril, with the best resolution located along the central portion of the map. B. Cross-section of the local resolution map of filamentous  $\alpha$ along the central portion of the map. B. Cross-section of the local resolution map of filamentous  $\alpha$ -syn



1981 real-space refinement in Phenix. We encourage users of this protocol to review tutorials and manuals for<br>1982 ChimeraX, Coot, and Phenix before proceeding with model building [40-42,46,47]. During the modeling 1982 ChimeraX, Coot, and Phenix before proceeding with model building [40-42,46,47]. During the modeling<br>1983 process users should use our refined model PDB 9CK3 as a reference. An overview of the entire modeling 1983 process users should use our refined model PDB 9CK3 as a reference. An overview of the entire modeling and validation workflow is provided for reference (Figure 14). validation workflow is provided for reference (Figure 14).





Figure 14. Model building and validation protocol for  $\alpha$ -synuclein fibrils. Step by step protocol for 1988 building, refining, and validating a  $\alpha$ -synuclein fibril molecular model. This protocol uses ChimeraX, Coot, and 1989 Phenix in an iterative fashion to improve the molecular model. Phenix in an iterative fashion to improve the molecular model.



2047 molecule), under *From Chain ID* select either chain, under *Using Residue Selection* select *Whole Chain*, 2048 under *To Chain ID* set this value to *A*, then click *Apply New Chain ID*. Repeat the process if the se 2048 under *To Chain ID* set this value to *A*, then click *Apply New Chain ID*. Repeat the process if the second fragment is labeled anything other than chain A. The fragments should now be one molecule labeled as 2049 fragment is labeled anything other than chain A. The fragments should now be one molecule labeled as chain A with a dotted line showing the missing residues from residues 23 to 36 that are not resolved.

- 2050 chain A with a dotted line showing the missing residues from residues 23 to 36 that are not resolved.<br>2051 17. Refine the new molecule that spans residues 15-22 and 37-98. Go to Refine  $\rightarrow$  All-atom Refine, if the 2051 17. Refine the new molecule that spans residues 15-22 and 37-98. Go to *Refine* <sup>à</sup> *All-atom Refine*, if the atoms 2052 are well positioned click *Accept*. If not, manually adjust misplaced atoms by dragging the atoms into place<br>2053 and then click *Accept*. and then click *Accept*.
- 2054 18. Save the coordinates, go to *File*  $\rightarrow$  *Save Coordinates*, under *Select Molecule Number to Save* select the molecules that was refined in step 17, click *Select Filename* and save the file to the desired locati 2055 molecules that was refined in step 17, click *Select Filename* and save the file to the desired location.<br>2056 19. Open Phenix and setup a new project. 19. Open Phenix and setup a new project.
- 2057 NOTE: We encourage new users to review the Phenix tutorial, specifically the real space refinement 2058 tutorial, to become familiar with the software before proceeding (https://phenix-2058 tutorial, to become familiar with the software before proceeding (https://phenix-<br>2059 online.org/documentation/reference/real space refine.html) 2059 <u>online.org/documentation/reference/real\_space\_refine.html</u>)<br>2060 20. Under the crvo-Em section select the *Real-space refinement*
- 2060 20. Under the cryo-Em section select the *Real-space refinement* job. Provide the PDB file from Coot as the model file and the postprocessed file as the map file. Set *Resolution* as determined in the final RELION 2061 model file and the postprocessed file as the map file. Set *Resolution* as determined in the final RELION 2062 postprocessing job, in this case the resolution is 2.04 Å. Under the *Refinement Settings* tab, in addition to 2063 the default settings ensure *Use secondary structure restraints* and *Ramachandran restraints* is checked, set 2064 *Nproc* to 4, click *Rotamers* and under *Fit* select *outliers and poormap*, then click *Run*. Upon 2064 *Nproc* to 4, click *Rotamers* and under *Fit* select *outliers and poormap*, then click *Run*. Upon completion, 2065 the validation report shows that the model statistics are favorable. The *Rotamer outliers (%)* will be slightly elevated due to a salt bridge that forms between lysine 80 and glutamic acid 46, causing lysine 80 to be 2066 elevated due to a salt bridge that forms between lysine 80 and glutamic acid 46, causing lysine 80 to be a<br>2067 totamer outlier that is supported by the data. 2067 rotamer outlier that is supported by the data.<br>2068 21. In ChimeraX, open the refined model and the
- 21. In ChimeraX, open the refined model and the postprocessed map. Open the refined model again and now 2069 two models are available. Select the second model and use the *Fit* tool to place the second monomer into 2070 the opposing protofilament. Repeat the process of opening the refined model and fitting it into a new regi 2070 the opposing protofilament. Repeat the process of opening the refined model and fitting it into a new region 2071 of the map. For PDB 9CK3 we built a dodecamer model. 2071 of the map. For PDB 9CK3 we built a dodecamer model.<br>2072 22. Once the desired number of subunits are fitted into the ma
- 2072 22. Once the desired number of subunits are fitted into the map, run *combine* from the ChimeraX command 2073 line to merge the subunits into one model. The command should provide a unique chain ID to each subun line to merge the subunits into one model. The command should provide a unique chain ID to each subunit.
- 2074 23. Repeat step 6 to save the model relative to the postprocessed map.<br>2075 24. In Phenix, repeat real space refinement as in step 20 with the additional
- 2075 24. In Phenix, repeat real space refinement as in step 20 with the additional parameter *Ncs constraints* selected.<br>2076 The final validation report shows excellent model statistics with only lysine 80 as a rotamer ou 2076 The final validation report shows excellent model statistics with only lysine 80 as a rotamer outlier, as 2077 expected. This step can be repeated, if necessary. The model is now ready for structure analysis. expected. This step can be repeated, if necessary. The model is now ready for structure analysis.

# 2079 **Additional Validation.**

This protocol or parts of it has been used and validated in the following research articles:

- 2081 Dhavale, et al. [33]. Structure of alpha-synuclein fibrils derived from human Lewy boy dementia tissue. Nature Communications. https://doi.org/10.1038/s41467-024-46832-5.
- 2083 Montemayor et al. [48]. Flagellar Structures from the Bacterium Caulobacter crescentus and Implications 2084 for Phage φ CbK Predation of Multiflagellin Bacteria. Journal of 2085 Bacteriology. https://doi.org/10.1128/jb.00399-20. Bacteriology. https://doi.org/10.1128/jb.00399-20.
- 2086 Sanchez et al. [49]. Atomic-level architecture of Caulobacter crescentus flagellar filaments provide<br>2087 vidence for multi-flagellin filament stabilization. bioRxiv. https://doi.org/10.1101/2023.07.10.5484 2087 evidence for multi-flagellin filament stabilization. bioRxiv. https://doi.org/10.1101/2023.07.10.548443.
- **2088** The cryo-EM structure in the manuscript has been validated by our submissions to the PDB (9CK3) and EMDB (EMD-45639). https://doi.org/10.2210/pdb9CK3/pdb. EMDB (EMD-45639). https://doi.org/10.2210/pdb9CK3/pdb.

# 2090<br>2091

2078<br>2079

2091 **Discussion.**<br>2092 The fibriliza 2092 The fibrilization conditions presented here are specific to one form of *in vitro* assembled  $\alpha$ -synuclein fibrils.<br>2093 Extensive optimization of protein purification and fibrilization conditions, testing buffer co 2093 Extensive optimization of protein purification and fibrilization conditions, testing buffer conditions and incubation 2094 parameters, may be necessary to generate different *in vitro* forms. The cryo-EM helical recon 2094 parameters, may be necessary to generate different *in vitro* forms. The cryo-EM helical reconstruction methods 2095 presented here assume that fibrils are both twisting and are of sufficient length to determine the c 2095 presented here assume that fibrils are both twisting and are of sufficient length to determine the crossover distance 2096 for helical twist estimates. There are cases where fibrils may not twist and thus this workflo 2096 for helical twist estimates. There are cases where fibrils may not twist and thus this workflow would not be 2097 amendable to such samples. Finally, structure determination of patient derived fibrils is of high inter 2097 amendable to such samples. Finally, structure determination of patient derived fibrils is of high interest, but 2098 extraction of fibrils from patient tissue is outside of the scope of the work presented here. Though 2098 extraction of fibrils from patient tissue is outside of the scope of the work presented here. Though in theory, the data 2099 processing methods presented here should be applicable to these samples. processing methods presented here should be applicable to these samples.

2100<br>2101 2101 Cryo-EM data processing is dependent on the sample, data collection instrumentation and parameters used, and<br>2102 computational hardware and software. What we have presented here should provide users with the necessar computational hardware and software. What we have presented here should provide users with the necessary details

- 2103 for cryo-EM structure determination of a range of amyloid fibrils. We used this approach to generate a cryo-EM map
- 2104 and atomic model of *in vitro* assembled  $\alpha$ -synuclein fibrils; and atomic models were deposited in the Protein Data 2105 Bank (PDB) under accession 9CK3. Cryo-EM maps, including the final map, half-maps, and mask w Bank (PDB) under accession 9CK3. Cryo-EM maps, including the final map, half-maps, and mask were deposited
- 2106 in the Electron Microscopy Data Bank (EMDB) under accession EMD-45639.
- 2107<br>2108
- 2108 The work presented here, including sample preparation, NS-TEM, cryo-EM data collection, cryo-EM data 2109 processing, and molecular model building serves as a starting point for individuals new to cryo-EM structure. 2109 processing, and molecular model building serves as a starting point for individuals new to cryo-EM structural<br>2110 analyses of amyloid proteins. For cryo-EM structure determination, new samples will pose their own uni
- 2110 analyses of amyloid proteins. For cryo-EM structure determination, new samples will pose their own unique set of 2111 challenges, but by first completing the data processing workflow in section E with the EMPIAR datas
- 2111 challenges, but by first completing the data processing workflow in section E with the EMPIAR dataset under<br>2112 ccession EMPIAR-12229, new users will be more adept at troubleshooting new issues.
- accession EMPIAR-12229, new users will be more adept at troubleshooting new issues.
- 2113
- 2114

- 2115 **Acknowledgements.** This work was supported in part by the University of Wisconsin, Madison, the Department of 2116 Biochemistry at the University of Wisconsin, Madison, and public health service grants U24 GM139168 t 2116 Biochemistry at the University of Wisconsin, Madison, and public health service grants U24 GM139168 to E.R.W, 2117 P41GM136463 to C.M.R. and RF1 NS110436 E.R.W, and C.M.R. from the NIH. J.C.S. was supported in part by 2117 P41GM136463 to C.M.R, and RF1 NS110436 E.R.W. and C.M.R. from the NIH. J.C.S. was supported in part by the 2118 Biotechnology Training Program at the University of Wisconsin, Madison, T32 GM135066, the Steenbock<br>2119 Predoctoral Graduate Fellowship administered by the University of Wisconsin-Madison Department of 2119 Predoctoral Graduate Fellowship administered by the University of Wisconsin-Madison Department of 2120 Biochemistry, and the SciMed Graduate Research Scholars Fellowship with support for this fellowship 2120 Biochemistry, and the SciMed Graduate Research Scholars Fellowship with support for this fellowship provided by<br>2121 the Graduate School, part of the Office of Vice Chancellor for Research and Graduate Education at th 2121 the Graduate School, part of the Office of Vice Chancellor for Research and Graduate Education at the University of 2122 Wisconsin-Madison, with funding from the Wisconsin Alumni Research Foundation and the UW-Madison. C.G.B.<br>2123 was supported by the NIH Ruth L. Kirschstein Fellowship, F32 GM149118, from the NIGMS. We are grateful for 2123 was supported by the NIH Ruth L. Kirschstein Fellowship, F32 GM149118, from the NIGMS. We are grateful for<br>2124 the critical feedback, guidance, and support provided by Dr. Bryan Sibert, Dr. Matthew Larson, and Ms. Je 2124 the critical feedback, guidance, and support provided by Dr. Bryan Sibert, Dr. Matthew Larson, and Ms. Jennifer 2125 Scheuren on cryo-EM data collection, data processing, and use of the cryo-EM HPC cluster. We are grateful for the 2126 use of facilities and instrumentation at the Cryo-EM Research Center in the Department of Biochemi 2126 use of facilities and instrumentation at the Cryo-EM Research Center in the Department of Biochemistry at the 2127 University of Wisconsin, Madison. We are grateful for the computational resources supplied through the 2127 University of Wisconsin, Madison. We are grateful for the computational resources supplied through the SBGrid 2128 Consortium [50]. Consortium [50].
- 2129

# 2130 **Data deposition.**

2131 The atomic model was deposited in the Protein Data Bank under accession 9CK3. Cryo-EM maps were deposited in 2132 the Electron Microscopy Data Bank under accession EMD-45639. The raw micrographs, gain file, and detect

the Electron Microscopy Data Bank under accession EMD-45639. The raw micrographs, gain file, and detector

- 2133 MTF file are available on the EMPIAR-12229 database under accession EMPIAR-12229.
- 
- 2134<br>2135 Competing Interests. The authors declare no competing interests.

# 2136 **References** 2137<br>2138 1. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q. and Iwatsubo, T. 2139 (1998). Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with 2140 Lewy bodies. Am J Pathol 152(4): 879-884. 2140 Lewy bodies. *Am J Pathol* 152(4): 879-884. 2141 2. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R. and Goedert, M. (1997).<br>2142 Habha-synuclein in Lewy bodies. *Nature* 388(6645): 839-840. https://doi.org/10.1038/42166. 2142 Alpha-synuclein in Lewy bodies. *Nature* 388(6645): 839-840. https://doi.org/10.1038/42166. 2143 3. Tu, P. H., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, 2144 J. Q. and Lee, V. M. (1998). Glial cytoplasmic inclusions in white matter oligodendrocytes of mul 2144 J. Q. and Lee, V. M. (1998). Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44(3): 415-422. 2145 system atrophy brains contain insoluble alpha-synuclein. *Ann Neurol* 44(3): 415-422. 2146 https://doi.org/10.1002/ana.410440324.<br>2147 4. Eisenberg, D. S. and Sawaya, M. R. (20 2147 4. Eisenberg, D. S. and Sawaya, M. R. (2017). Structural Studies of Amyloid Proteins at the Molecular Level.<br>2148 *Annual Review of Biochemistry* 86(Volume 86, 2017): 69-95. 2148 *Annual Review of Biochemistry* 86(Volume 86, 2017): 69-95. 2149 https://doi.org/https://doi.org/10.1146/annurev-biochem-061516-045104.<br>2150 5. Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R. and Su Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R. and Sudhof, T. C. (2010). Alpha-2151 synuclein promotes SNARE-complex assembly in vivo and in vitro. *Science* 329(5999): 1663-1667.<br>2152 https://doi.org/10.1126/science.1195227. 2152 https://doi.org/10.1126/science.1195227.<br>2153 6. Davidson, W. S., Jonas, A., Clayton, D. I 2153 6. Davidson, W. S., Jonas, A., Clayton, D. F. and George, J. M. (1998). Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. *J Biol Chem* 273(16): 9443-9449. 2154 secondary structure upon binding to synthetic membranes. *J Biol Chem* 273(16): 9443-9449. 2155 https://doi.org/10.1074/jbc.273.16.9443.<br>2156 7. Lou, X., Kim, J., Hawk, B. J. and Shin, Y. 2156 7. Lou, X., Kim, J., Hawk, B. J. and Shin, Y. K. (2017). alpha-Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking. *Biochem J* 474(12): 2039-2049. 2157 acidic phospholipids to facilitate SNARE-dependent vesicle docking. *Biochem J* 474(12): 2039-2049. 2158 https://doi.org/10.1042/BCJ20170200.<br>2159 8. Sun, J., Wang, L., Bao, H., Premi, S., I 2159 8. Sun, J., Wang, L., Bao, H., Premi, S., Das, U., Chapman, E. R. and Roy, S. (2019). Functional cooperation<br>2160 of alpha-synuclein and VAMP2 in synaptic vesicle recycling. *Proc Natl Acad Sci U S A* 116(23): 11113-2160 of alpha-synuclein and VAMP2 in synaptic vesicle recycling. *Proc Natl Acad Sci U S A* 116(23): 11113-<br>2161 11115. https://doi.org/10.1073/pnas.1903049116. 2161 11115. https://doi.org/10.1073/pnas.1903049116.<br>2162 9. Thapa, K., Khan, H., Kanojia, N., Singh, T. G., K. 2162 9. Thapa, K., Khan, H., Kanojia, N., Singh, T. G., Kaur, A. and Kaur, G. (2022). Therapeutic Insights on 2163 Ferroptosis in Parkinson's disease. *Eur J Pharmacol* 930: 175133. 2164 https://doi.org/10.1016/j.ejphar.2022.175133.<br>2165 10. Serpell, L. C., Berriman, J., Jakes, R., Goeder 2165 10. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. and Crowther, R. A. (2000). Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. *Proc Natl Acad Sc* 2166 synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. *Proc Natl Acad Sci U S A* 2167 97(9): 4897-4902. https://doi.org/10.1073/pnas.97.9.4897.<br>2168 11. Spillantini, M. G. and Goedert, M. (2000). The alpha-synu 2168 11. Spillantini, M. G. and Goedert, M. (2000). The alpha-synucleinopathies: Parkinson's disease, dementia with<br>2169 Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920: 16-27. https://doi.org/10.1111/j.1749 2169 Lewy bodies, and multiple system atrophy. *Ann N Y Acad Sci* 920: 16-27. https://doi.org/10.1111/j.1749- 2170 6632.2000.tb06900.x.<br>2171 12. Guerrero-Ferreira, R., 2171 12. Guerrero-Ferreira, R., Taylor, N. M., Mona, D., Ringler, P., Lauer, M. E., Riek, R., Britschgi, M. and<br>2172 Stahlberg, H. (2018). Cryo-EM structure of alpha-synuclein fibrils. *Elife* 7. 2172 Stahlberg, H. (2018). Cryo-EM structure of alpha-synuclein fibrils. *Elife* 7.<br>2173 https://doi.org/10.7554/eLife.36402. 2173 https://doi.org/10.7554/eLife.36402.<br>2174 13. Li, Y., Zhao, C., Luo, F., Liu, Z., Gu 2174 13. Li, Y., Zhao, C., Luo, F., Liu, Z., Gui, X., Luo, Z., Zhang, X., Li, D., Liu, C. and Li, X. (2018). Amyloid 2175 fibril structure of alpha-synuclein determined by cryo-electron microscopy. *Cell Res* 28(9): 897-903. 2176 https://doi.org/10.1038/s41422-018-0075-x.<br>2177 14. Tuttle, M. D., Comellas, G., Nieuwkoop, A. 2177 14. Tuttle, M. D., Comellas, G., Nieuwkoop, A. J., Covell, D. J., Berthold, D. A., Kloepper, K. D., Courtney, J.<br>2178 M., Kim, J. K., Barclay, A. M., Kendall, A., et al. (2016). Solid-state NMR structure of a pathogen M., Kim, J. K., Barclay, A. M., Kendall, A., et al. (2016). Solid-state NMR structure of a pathogenic fibril 2179 of full-length human alpha-synuclein. *Nat Struct Mol Biol* 23(5): 409-415.<br>2180 https://doi.org/10.1038/nsmb.3194. 2180 https://doi.org/10.1038/nsmb.3194.<br>2181 15. Lei, Z., Cao, G. and Wei, G. (2019) Lei, Z., Cao, G. and Wei, G. (2019). A30P mutant alpha-synuclein impairs autophagic flux by inactivating 2182 JNK signaling to enhance ZKSCAN3 activity in midbrain dopaminergic neurons. *Cell Death Dis* 10(2):<br>2183 133. https://doi.org/10.1038/s41419-019-1364-0. 2183 133. https://doi.org/10.1038/s41419-019-1364-0.<br>2184 16. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., L 2184 16. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., 2185 Rodriguez, O., Atares, B., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkin 2185 Rodriguez, O., Atares, B., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and 2186 Lewy body dementia. Ann Neurol 55(2): 164-173. https://doi.org/10.1002/ana.10795. 2186 Lewy body dementia. *Ann Neurol* 55(2): 164-173. https://doi.org/10.1002/ana.10795. 2187 17. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., 2188 Thompson, C., Szu-Tu, C., Trinh, J., et al. (2013). Alpha-synuclein p.H50Q, a novel pathogenic m 2188 Thompson, C., Szu-Tu, C., Trinh, J., et al. (2013). Alpha-synuclein p.H50Q, a novel pathogenic mutation<br>2189 for Parkinson's disease. *Mov Disord* 28(6): 811-813. https://doi.org/10.1002/mds.25421. 2189 for Parkinson's disease. *Mov Disord* 28(6): 811-813. https://doi.org/10.1002/mds.25421.

- 2190 18. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L., Madiona, K., Durr, A., 2191 Melki, R., et al. (2013). G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndr 2191 Melki, R., et al. (2013). G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome.<br>2192 *Ann Neurol 73(4): 459-471.* https://doi.org/10.1002/ana.23894. 2192 *Ann Neurol* 73(4): 459-471. https://doi.org/10.1002/ana.23894.<br>2193 19. Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakko
- 2193 19. Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tienari, P. J., Poyhonen, 2194 M. and Paetau, A. (2014). Novel alpha-synuclein mutation A53E associated with atvoical multiple sy 2194 M. and Paetau, A. (2014). Novel alpha-synuclein mutation A53E associated with atypical multiple system<br>2195 atrophy and Parkinson's disease-type pathology. *Neurobiol Aging* 35(9): 2180 e2181-2185. 2195 atrophy and Parkinson's disease-type pathology. *Neurobiol Aging* 35(9): 2180 e2181-2185.<br>2196 https://doi.org/10.1016/j.neurobiolaging.2014.03.024. https://doi.org/10.1016/j.neurobiolaging.2014.03.024.
- 2197 20. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., 2198 Rubenstein, J., Boyer, R., et al. (1997). Mutation in the alpha-synuclein gene identified in families wi 2198 Rubenstein, J., Boyer, R., et al. (1997). Mutation in the alpha-synuclein gene identified in families with<br>2199 Parkinson's disease. Science 276(5321): 2045-2047. https://doi.org/10.1126/science.276.5321.2045. 2199 Parkinson's disease. *Science* 276(5321): 2045-2047. https://doi.org/10.1126/science.276.5321.2045.
- 2200 21. Yoshino, H., Hirano, M., Stoessl, A. J., Imamichi, Y., Ikeda, A., Li, Y., Funayama, M., Yamada, I., 2201 Nakamura, Y., Sossi, V., et al. (2017). Homozygous alpha-synuclein p.A53V in familial Parkinson' 2201 Nakamura, Y., Sossi, V., et al. (2017). Homozygous alpha-synuclein p.A53V in familial Parkinson's<br>2202 disease. *Neurobiol Aging* 57: 248 e247-248 e212. https://doi.org/10.1016/j.neurobiolaging.2017.05.0
- 2202 disease. *Neurobiol Aging* 57: 248 e247-248 e212. https://doi.org/10.1016/j.neurobiolaging.2017.05.022.<br>2203 22. Frey, L., Ghosh, D., Qureshi, B. M., Rhyner, D., Guerrero-Ferreira, R., Pokharna, A., Kwiatkowski, W., 2203 22. Frey, L., Ghosh, D., Qureshi, B. M., Rhyner, D., Guerrero-Ferreira, R., Pokharna, A., Kwiatkowski, W., 2204 Serdiuk, T., Picotti, P., Riek, R., et al. (2023). On the pH-dependence of α-synuclein amyloid Serdiuk, T., Picotti, P., Riek, R., et al. (2023). On the pH-dependence of  $\alpha$ -synuclein amyloid
- 2205 polymorphism and the role of secondary nucleation in seed-based amyloid propagation.<br>2206 23. Mehra, S., Gadhe, L., Bera, R., Sawner, A. S. and Maji, S. K. (2021). Structural and Fun 2206 23. Mehra, S., Gadhe, L., Bera, R., Sawner, A. S. and Maji, S. K. (2021). Structural and Functional Insights into  $\alpha$ -Synuclein Fibril Polymorphism. *Biomolecules* 11(10): 1419.
- 2207 into α-Synuclein Fibril Polymorphism. *Biomolecules* 11(10): 1419. 2208 24. Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute,  $C$ , Melki, R. and Baekelandt, V. (2015).  $\alpha$ -Synuclein strains cause distinct synucleinopathies after lo 2209 C., Melki, R. and Baekelandt, V. (2015).  $\alpha$ -Synuclein strains cause distinct synucleinopathies after local and systemic administration. *Nature* 522(7556): 340-344. https://doi.org/10.1038/nature14547. 2210 systemic administration. *Nature* 522(7556): 340-344. https://doi.org/10.1038/nature14547.<br>2211 25. Marotta, N. P., Ara, J., Uemura, N., Lougee, M. G., Meymand, E. S., Zhang, B., Petersson,
- 2211 25. Marotta, N. P., Ara, J., Uemura, N., Lougee, M. G., Meymand, E. S., Zhang, B., Petersson, E. J., Trojanowski, J. Q. and Lee, V. M. Y. (2021). Alpha-synuclein from patient Lewy bodies exhibits 2212 Trojanowski, J. Q. and Lee, V. M. Y. (2021). Alpha-synuclein from patient Lewy bodies exhibits distinct 2213 pathological activity that can be propagated in vitro. Acta Neuropathologica Communications 9(1): 188. 2213 pathological activity that can be propagated in vitro. *Acta Neuropathologica Communications* 9(1): 188.<br>2214 https://doi.org/10.1186/s40478-021-01288-2. 2214 https://doi.org/10.1186/s40478-021-01288-2.<br>2215 26. Uemura, N., Marotta, N. P., Ara, J., Meyman
- 2215 26. Uemura, N., Marotta, N. P., Ara, J., Meymand, E. S., Zhang, B., Kameda, H., Koike, M., Luk, K. C., 2216 Trojanowski, J. Q. and Lee, V. M. Y. (2023). a-Synuclein aggregates amplified from patient-derived I 2216 Trojanowski, J. Q. and Lee, V. M. Y. (2023). α-Synuclein aggregates amplified from patient-derived Lewy 2217 bodies recapitulate Lewy body diseases in mice. *Nature Communications* 14(1): 6892.<br>2218 https://doi.org/10.1038/s41467-023-42705-5.
- 2218 https://doi.org/10.1038/s41467-023-42705-5.<br>2219 27. Yang, Y., Shi, Y., Schweighauser, M., Zhang, 2219 27. Yang, Y., Shi, Y., Schweighauser, M., Zhang, X., Kotecha, A., Murzin, A. G., Garringer, H. J., Cullinane, P.<br>2220 W., Saito, Y., Foroud, T., et al. (2022). Structures of a-synuclein filaments from human brains wit W., Saito, Y., Foroud, T., et al. (2022). Structures of  $\alpha$ -synuclein filaments from human brains with Lewy 2221 pathology. *Nature* 610(7933): 791-795. https://doi.org/10.1038/s41586-022-05319-3.<br>2222 28. Riek, R. and Eisenberg, D. S. (2016). The activities of amyloids from a structural per
- 2222 28. Riek, R. and Eisenberg, D. S. (2016). The activities of amyloids from a structural perspective. *Nature*<br>2223 539(7628): 227-235. https://doi.org/10.1038/nature20416. 2223 539(7628): 227-235. https://doi.org/10.1038/nature20416.<br>2224 29. Jarrett, J. T. and Lansbury, P. T., Jr. (1992). Amyloid fibril
- 2224 29. Jarrett, J. T. and Lansbury, P. T., Jr. (1992). Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. *Biochemistry* 2225 nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. *Biochemistry*<br>2226 31(49): 12345-12352. https://doi.org/10.1021/bi00164a008. 2226 31(49): 12345-12352. https://doi.org/10.1021/bi00164a008.<br>2227 30. Tornquist, M., Michaels, T. C. T., Sanagavarapu, K., Yang, Y
- 2227 30. Tornquist, M., Michaels, T. C. T., Sanagavarapu, K., Yang, X., Meisl, G., Cohen, S. I. A., Knowles, T. P. J. 2228 and Linse, S. (2018). Secondary nucleation in amyloid formation. *Chem Commun (Camb)* 54(63): 8667-2228 and Linse, S. (2018). Secondary nucleation in amyloid formation. *Chem Commun (Camb)* 54(63): 8667-
- 2229 8684. https://doi.org/10.1039/c8cc02204f.<br>2230 31. Tanaka, G., Yamanaka, T., Furukawa, Y., I 2230 31. Tanaka, G., Yamanaka, T., Furukawa, Y., Kajimura, N., Mitsuoka, K. and Nukina, N. (2019). Sequence- and seed-structure-dependent polymorphic fibrils of alpha-synuclein. *Biochimica et Biophysica Acta (BBA)* -2231 seed-structure-dependent polymorphic fibrils of alpha-synuclein. *Biochimica et Biophysica Acta (BBA) -* 2232 *Molecular Basis of Disease* 1865(6): 1410-1420.
- 2233 https://doi.org/https://doi.org/10.1016/j.bbadis.2019.02.013.<br>2234 32. Strohäker, T., Jung, B. C., Liou, S.-H., Fernandez, C. O., Rie
- 2234 32. Strohäker, T., Jung, B. C., Liou, S.-H., Fernandez, C. O., Riedel, D., Becker, S., Halliday, G. M., Bennati, 2235 M., Kim, W. S., Lee, S.-J., et al. (2019). Structural heterogeneity of  $\alpha$ -synuclein fibrils ampli M., Kim, W. S., Lee, S.-J., et al. (2019). Structural heterogeneity of  $\alpha$ -synuclein fibrils amplified from
- 2236 patient brain extracts. *Nature Communications* 10(1): 5535. https://doi.org/10.1038/s41467-019-13564-w.<br>2237 33. Dhavale, D. D., Barclay, A. M., Borcik, C. G., Basore, K., Berthold, D. A., Gordon, I. R., Liu, J., 2237 33. Dhavale, D. D., Barclay, A. M., Borcik, C. G., Basore, K., Berthold, D. A., Gordon, I. R., Liu, J., 2238 Milchberg, M. H., O'Shea, J. Y., Rau, M. J., et al. (2024). Structure of alpha-synuclein fibrils deri 2238 Milchberg, M. H., O'Shea, J. Y., Rau, M. J., et al. (2024). Structure of alpha-synuclein fibrils derived from<br>2239 human Lewy body dementia tissue. *Nature Communications* 15(1): 2750. https://doi.org/10.1038/s41467-2239 human Lewy body dementia tissue. *Nature Communications* 15(1): 2750. https://doi.org/10.1038/s41467-
- **2240** 024-46832-5.<br> **2241** 34. **Naiki**, H., Hig 2241 34. Naiki, H., Higuchi, K., Hosokawa, M. and Takeda, T. (1989). Fluorometric determination of amyloid fibrils 2242 in vitro using the fluorescent dye, thioflavine T. *Analytical Biochemistry* 177(2): 244-249.<br>2243 https://doi.org/https://doi.org/10.1016/0003-2697(89)90046-8. https://doi.org/https://doi.org/10.1016/0003-2697(89)90046-8.

- 2244 35. Kimanius, D., Dong, L., Sharov, G., Nakane, T. and Scheres, S. H. W. (2021). New tools for automated<br>2245 crvo-EM single-particle analysis in RELION-4.0. *Biochem J* 478(24): 4169-4185. 2245 cryo-EM single-particle analysis in RELION-4.0. *Biochem J* 478(24): 4169-4185. 2246 https://doi.org/10.1042/bcj20210708.<br>2247 36. Zheng, S. Q., Palovcak, E., Armache,
- 2247 36. Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y. and Agard, D. A. (2017). MotionCor2:<br>2248 anisotropic correction of beam-induced motion for improved crvo-electron microscopy. Nat Methods 14(4) 2248 anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* 14(4):<br>2249 331-332. https://doi.org/10.1038/nmeth.4193.
- 2249 331-332. https://doi.org/10.1038/nmeth.4193.<br>2250 37. Zhang, K. (2016). Gctf: Real-time CTF deterr 2250 37. Zhang, K. (2016). Gctf: Real-time CTF determination and correction. *J Struct Biol* 193(1): 1-12.
- 2251 https://doi.org/https://doi.org/10.1016/j.jsb.2015.11.003.<br>2252 38. Bepler, T., Morin, A., Rapp, M., Brasch, J., Shapiro, L., 1 2252 38. Bepler, T., Morin, A., Rapp, M., Brasch, J., Shapiro, L., Noble, A. J. and Berger, B. (2019). Positive-<br>2253 bunlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Nat Meth 2253 unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. *Nat Methods* 2254 16(11): 1153-1160. https://doi.org/10.1038/s41592-019-0575-8.<br>2255 39. Scheres, S. H. W. (2020). Amyloid structure determination in RI
- 2255 39. Scheres, S. H. W. (2020). Amyloid structure determination in RELION-3.1. *Acta Crystallogr D Struct Biol* 2256 76(Pt 2): 94-101. https://doi.org/10.1107/S2059798319016577.<br>2257 40. Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Co
- 2257 40. Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. I., Morris, J. H. and<br>2258 Ferrin, T. E. (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and develope Ferrin, T. E. (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and developers. 2259 *Protein Sci* 30(1): 70-82. https://doi.org/10.1002/pro.3943.<br>2260 41. Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F.
- 2260 41. Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H. and Ferrin, T. E.<br>2261 (2018). UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci* 27(1): 2261 (2018). UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci* 27(1): 14- 2262 25. https://doi.org/10.1002/pro.3235.<br>2263 42. Meng, E. C., Goddard, T. D., Petterse
- 2263 42. Meng, E. C., Goddard, T. D., Pettersen, E. F., Couch, G. S., Pearson, Z. J., Morris, J. H. and Ferrin, T. E.<br>2264 (2023). UCSF ChimeraX: Tools for structure building and analysis. *Protein Sci* 32(11): e4792. 2264 (2023). UCSF ChimeraX: Tools for structure building and analysis. *Protein Sci* 32(11): e4792. https://doi.org/10.1002/pro.4792.
- 2266 43. Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., 2267 6hetti, B., Goedert, M. and Scheres, S. H. W. (2017). Cryo-EM structures of tau filaments from 2267 Ghetti, B., Goedert, M. and Scheres, S. H. W. (2017). Cryo-EM structures of tau filaments from<br>2268 Alzheimer's disease. *Nature* 547(7662): 185-190. https://doi.org/10.1038/nature23002.
- 2268 Alzheimer's disease. *Nature* 547(7662): 185-190. https://doi.org/10.1038/nature23002. 2269 44. Yang, Y., Garringer, H. J., Shi, Y., Lovestam, S., Peak-Chew, S., Zhang, X., Kotecha, A., Bacioglu, M., 2270 Koto, A., Takao, M., et al. (2023). New SNCA mutation and structures of alpha-synuclein filaments fro Koto, A., Takao, M., et al. (2023). New SNCA mutation and structures of alpha-synuclein filaments from 2271 juvenile-onset synucleinopathy. *Acta Neuropathol* 145(5): 561-572. https://doi.org/10.1007/s00401-023-
- 2272 02550-8. 2273 45. Egelman, E. H. (2024). Helical reconstruction, again. *Current Opinion in Structural Biology* 85: 102788. https://doi.org/https://doi.org/10.1016/j.sbi.2024.102788.
- 2275 46. Emsley, P., Lohkamp, B., Scott, W. G. and Cowtan, K. (2010). Features and development of Coot. *Acta*  2276 *Crystallogr D* 66: 486-501. https://doi.org/10.1107/S0907444910007493.
- 2277 47. Liebschner, D., Afonine, P. V., Baker, M. L., Bunkoczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.<br>2278 W., Jain, S., McCoy, A. J., et al. (2019). Macromolecular structure determination using X-rays, neut 2278 W., Jain, S., McCoy, A. J., et al. (2019). Macromolecular structure determination using X-rays, neutrons 2279 and electrons: recent developments in Phenix. *Acta Crystallogr D Struct Biol* 75(Pt 10): 861-877. 2279 and electrons: recent developments in Phenix. *Acta Crystallogr D Struct Biol* 75(Pt 10): 861-877.<br>2280 https://doi.org/10.1107/S2059798319011471. 2280 https://doi.org/10.1107/S2059798319011471.<br>2281 48. Montemayor, E. J., Ploscariu, N. T., Sanchez,
- 2281 48. Montemayor, E. J., Ploscariu, N. T., Sanchez, J. C., Parrell, D., Dillard, R. S., Shebelut, C. W., Ke, Z., 2282 Guerrero-Ferreira, R. C. and Wright, E. R. (2021). Flagellar Structures from the Bacterium Caulobacter 2283 crescentus and Implications for Phage varphi CbK Predation of Multiflagellin Bacteria. *J Bacteriol* 203(5). 2284 https://doi.org/10.1128/JB.00399-20.<br>2285 49. Sanchez, J. C., Montemayor, E. J., Pl
- 2285 49. Sanchez, J. C., Montemayor, E. J., Ploscariu, N. T., Parrell, D., Baumgardt, J. K., Yang, J. E., Sibert, B., 2286 Cai, K. and Wright, E. R. (2023). Atomic-level architecture of Caulobacter crescentus flagellar fil Cai, K. and Wright, E. R. (2023). Atomic-level architecture of Caulobacter crescentus flagellar filaments 2287 provide evidence for multi-flagellin filament stabilization. *bioRxiv*.<br>2288 https://doi.org/10.1101/2023.07.10.548443.
- 2288 https://doi.org/10.1101/2023.07.10.548443.<br>2289 50. Morin, A., Eisenbraun, B., Key, J., Sanscha Morin, A., Eisenbraun, B., Key, J., Sanschagrin, P. C., Timony, M. A., Ottaviano, M. and Sliz, P. (2013). 2290 Collaboration gets the most out of software. *Elife* 2: e01456. https://doi.org/10.7554/eLife.01456.
- 2291